ARCHIVES

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Conversation With The Cancer Letter: Seffrin To Retire After Restructuring ACS

January 24, 2014

Emphasis On Early Disease In Clinical Trials, Early Lung Cancer Detection Seen As “Landmark”

September 19, 1975

In Brief: Ma and Tyner Receive Award From AAAS

July 4, 2014

Test May Identify Predictors For Recurrence Post-Surgery

January 28, 2011

NCI Establishes New Program Project Grant Guidelines.

January 13, 2006

New Immunotherapy Increased Survival Of Neuroblastoma In Phase III Trial

September 24, 2010